×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ALVO – alvotech (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ALVO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/21
02:04 am
alvo
Alvotech's Position In The Coming Biosimilar Gold Rush [Seeking Alpha]
Low
Report
Alvotech's Position In The Coming Biosimilar Gold Rush [Seeking Alpha]
11/15
02:22 am
alvo
Alvotech (ALVO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Advancements [Yahoo! Finance]
Low
Report
Alvotech (ALVO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Advancements [Yahoo! Finance]
11/13
09:26 pm
alvo
Alvotech (ALVO) Q3 Earnings and Revenues Beat Estimates [Yahoo! Finance]
Medium
Report
Alvotech (ALVO) Q3 Earnings and Revenues Beat Estimates [Yahoo! Finance]
11/13
04:22 pm
alvo
Alvotech Reports Financial Results for the First Nine Months of 2024 [Yahoo! Finance]
Medium
Report
Alvotech Reports Financial Results for the First Nine Months of 2024 [Yahoo! Finance]
11/13
04:05 pm
alvo
Alvotech Reports Financial Results for the First Nine Months of 2024
Medium
Report
Alvotech Reports Financial Results for the First Nine Months of 2024
11/7
08:00 am
alvo
Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024
Low
Report
Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024
11/4
07:00 am
alvo
European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)
Low
Report
European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)
10/30
08:30 am
alvo
Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET
Low
Report
Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/13
05:24 pm
alvo
Form 6-K Alvotech For: Nov 13
Medium
Report
Form 6-K Alvotech For: Nov 13
11/6
01:52 pm
alvo
Form SC 13G/A Alvotech Filed by: YA II PN, Ltd.
Low
Report
Form SC 13G/A Alvotech Filed by: YA II PN, Ltd.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: